Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

Inclusion Criteria

• •Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
• •Participants with Histologically or cytologically confirmed SCLC:
• •For Part 1, participants must have SCLC that has progressed or recurred following at least 1 line of platinum-based anti-cancer therapy.
• •For Parts 1 and 2, participants must have progressed or recurred following at least 1 line of platinum-based therapy. No prior tarlatamab is allowed in Cohort 2-1.
• •For Part 3, participants must have extensive-stage SCLC (ES-SCLC) with no prior systemic treatment other than 1 cycle of platinum-based chemotherapy.
• •Note: Participants with prior treatment for limited-stage SCLC (LS-SCLC) before diagnosis of ES SCLC are permitted.
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• •At least 1 measurable lesion as defined per RECIST v1.1 within 21-day screening period, not previously irradiated.
• •Adequate organ function (hematological, coagulation, renal, hepatic, pulmonary, and cardiac function).